The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR

@article{Kao2018TheAD,
  title={The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR},
  author={J. Kao and Wei-Chun HuangFu and Tsung-Ting Tsai and Min-Ru Ho and Ming-Kai Jhan and T. Shen and Po-Chun Tseng and Yung-Ting Wang and Chiou-Feng Lin},
  journal={PLoS Neglected Tropical Diseases},
  year={2018},
  volume={12}
}
Background The antiparasitic agent niclosamide has been demonstrated to inhibit the arthropod-borne Zika virus. Here, we investigated the antiviral capacity of niclosamide against dengue virus (DENV) serotype 2 infection in vitro and in vivo. Principle finding Niclosamide effectively retarded DENV-induced infection in vitro in human adenocarcinoma cells (A549), mouse neuroblastoma cells (Neuro-2a), and baby hamster kidney fibroblasts (BHK-21). Treatment with niclosamide did not retard the… Expand
Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication.
TLDR
In vitro data indicated that niclosamide hindered RSV infection via proapoptotic activity by a reduction of AKT prosurvival protein, activation of cleaved caspase-3 and PARP (poly ADP-ribose polymerase), and an early apoptosis induction. Expand
Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition
TLDR
The findings demonstrated the antiviral mechanism of niclosamide is via the AMPK-mTORC1 pathway, which could be a common therapeutic target for various viruses. Expand
JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both in vitro and in vivo.
TLDR
A niclosamide derivative JMX0207 was identified which shows improved pharmacokinetics and efficacy against Zika virus both in vitro and in vivo and significantly reduced viremia in a ZIKV animal model. Expand
Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro
TLDR
It is revealed that neutralization of low-pH intracellular compartments by niclosamide affects multiple steps of the DENV infectious cycle, and a previously uncharacterized mechanism of action of the drug is highlighted. Expand
Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
TLDR
Novel activities of obatoclax and emetine are identified against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests. Expand
Developing Cytokine Storm-Sensitive Therapeutic Strategy in COVID-19 Using 8P9R Chimeric Peptide and Soluble ACE2
Currently, the COVID-19 pandemic is an international challenge, largely due to lack of effective therapies. Pharmacotherapy has not yet been able to find a definitive treatment for COVID-19. SinceExpand
Zika virus pathogenesis and current therapeutic advances
TLDR
A comprehensive summary of the viral pathogenesis of ZIKV and current advancements in the development of vaccines and drugs against this virus is provided. Expand
Activation of the autophagy pathway affects Dengue virus infection in Aedes aegypti
TLDR
The practicality ofSmall molecules in altering the autophagy pathway in mosquitoes, and thus the usage of small molecules as possible mosquito pathogen vaccines should be evaluated, is proved. Expand
Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses
TLDR
The potency of eight drugs known to block EBOV entry with their potency as inhibitors of LASV entry were directly compared and arbidol, a drug licensed abroad as an anti-influenza drug, was found to block fusion mediated by the Lassa virus glycoprotein. Expand
Antiviral Compounds for Blocking Arboviral Transmission in Mosquitoes
TLDR
Recent advances in small-molecule antiarboviral drugs in mammalian and mosquito cells are summarized, and how to use these antivirals to block the transmission of MBVDs is discussed. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 38 REFERENCES
Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral Effects
TLDR
It is demonstrated that physico-chemical interference with host pathways has broad range antiviral effects, and provides a proof of concept for the development of host-directed antivirals. Expand
Suppressing Dengue-2 Infection by Chemical Inhibition of Aedes aegypti Host Factors
TLDR
Proof-of-principle is provided that chemical inhibition or RNAi-mediated depletion of the DENV HFs vATPase and IMPDH can be used to suppress DENV infection of adult A. aegypti mosquitoes, which may translate to a reduction in DENV transmission. Expand
Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission
TLDR
It is suggested that niclosamide and nitazoxanide were able to inhibit Chikungunya virus entry and transmission, which might provide a basis for the development of novel human drug therapies against CHIKV and other alphavirus infections. Expand
Niclosamide inhibits lytic replication of Epstein‐Barr virus by disrupting mTOR activation
TLDR
It is concluded that niclosamide is a promising candidate for chemotherapy against the acute occurrence and transmission of infectious diseases of oncogenic &ggr;‐herpesviruses. Expand
Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen
TLDR
A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures, and combination treatments using one compound from each category (neuroprotective and antiviral) further increased protection of human neural progensitors and astrocytes from ZIKv-induced cell death. Expand
Novel Dengue Virus NS2B/NS3 Protease Inhibitors
TLDR
The selective and noncompetitive inhibition of the serotype 2 and 3 dengue virus PR in vitro and in cells by benzothiazole derivatives exhibiting 50% inhibitory concentrations (IC50s) in the low-micromolar range is reported. Expand
Blockade of dengue virus infection and viral cytotoxicity in neuronal cells in vitro and in vivo by targeting endocytic pathways
TLDR
Results demonstrate that clathrin mediated endocytosis of DENV followed by endosomal acidification-dependent viral replication in neuronal cells, which can lead to neurotoxicity, is demonstrated. Expand
Recent trends in ZikV research: A step away from cure.
TLDR
Few pharmacological agents like Mycophenolicacid, Niclosamide, PHA-690509, Emricasan and Bortezomib are most potent anti-ZikV candidates and highly effective single or combining treatment with these drugs. Expand
Niclosamide: Beyond an antihelminthic drug
TLDR
A brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases are provided. Expand
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
TLDR
The inhibitory effects of niclosamide on cancer stem cells provide further evidence for its consideration as a promising drug for cancer therapy. Expand
...
1
2
3
4
...